Xencor, Inc.

Dana-farber-cancer Institute Inc.

Pankaj Seth

John R Desjarlais

Gregory L Moore

Michael Hedvat

Kornelia Polyak

Dale Porter

Juan Diaz

Adam Zwolak

Fei Shen

Matthew Adam Dragovich

Veronica Gusti Zeng

Joseph Erhardt

Fouad Moussa

Theresa McDevitt

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

Growing community of inventors

Norristown, PA, United States of America

Pankaj Seth